The newly established deal includes the co-development of up to three T-cell therapies, by utilizing the latter’s stem-cell derived allogeneic T-cell platform.
Gavi establishes an Ebola vaccine program for the next five years, with a stockpile of vaccines created to be made available to low- and middle-income countries free of charge.
WuXi Biologics furthers its manufacturing presence in Ireland with a manufacturing facility for its vaccines subsidiary, which will be able to produce both drug substance and drug product.
